keyword
https://read.qxmd.com/read/38538345/genetics-and-age-related-macular-degeneration-a-practical-review-for-clinicians
#21
REVIEW
Julia Nguyen, Milam A Brantley, Stephen G Schwartz
Age-related macular degeneration (AMD) is a multifactorial genetic disease, with at least 52 identifiable associated gene variants at 34 loci, including variants in complement factor H ( CFH ) and age-related maculopathy susceptibility 2/high-temperature requirement A serine peptidase-1 ( ARMS2/HTRA1 ). Genetic factors account for up to 70% of disease variability. However, population-based genetic risk scores are generally more helpful for clinical trial design and stratification of risk groups than for individual patient counseling...
February 29, 2024: Frontiers in Bioscience (Scholar Edition)
https://read.qxmd.com/read/38534576/hydrogel-based-therapy-for-age-related-macular-degeneration-current-innovations-impediments-and-future-perspectives
#22
REVIEW
Chengzhi Zhang, Jiale Wang, Hao Wu, Wenhui Fan, Siyu Li, Dong Wei, Zongming Song, Ye Tao
Age-related macular degeneration (AMD) is an ocular disease that leads to progressive photoreceptor death and visual impairment. Currently, the most common therapeutic strategy is to deliver anti-vascular endothelial growth factor (anti-VEGF) agents into the eyes of patients with wet AMD. However, this treatment method requires repeated injections, which potentially results in surgical complications and unwanted side effects for patients. An effective therapeutic approach for dry AMD also remains elusive. Therefore, there is a surge of enthusiasm for the developing the biodegradable drug delivery systems with sustained release capability and develop a promising therapeutic strategy...
February 21, 2024: Gels
https://read.qxmd.com/read/38534392/eye-drop-with-fas-blocking-peptide-attenuates-age-related-macular-degeneration
#23
JOURNAL ARTICLE
Yujong Yi, Seon-Hong Pyun, Chae-Yeon Kim, Gyeongju Yun, Eunhwa Kang, Seoyoun Heo, Irfan Ullah, Sang-Kyung Lee
Age-related macular degeneration (AMD), characterized by macular retinal degeneration, poses a significant health concern due to the lack of effective treatments for prevalent dry AMD. The progression of AMD is closely linked to reactive oxygen species and Fas signaling, emphasizing the need for targeted interventions. In this study, we utilized a NaIO3 -induced retinal degeneration mouse model to assess the efficacy of Fas-blocking peptide (FBP). Intravitreal administration of FBP successfully suppressed Fas-mediated inflammation and apoptosis, effectively arresting AMD progression in mice...
March 20, 2024: Cells
https://read.qxmd.com/read/38531681/central-serous-chorioretinopathy-a-review
#24
REVIEW
Manethová Myslík, Kateřina
Central serous chorioretinopathy (CSC) is a disease characterized by serous detachment of the neuroretina, especially in the posterior pole of the eye. It is often accompanied by serous detachment of the retinal pigment epithelium (RPE) and associated with the leakage of fluid into the subretinal space through the defective RPE. CSC most often affects men of working age. The exact pathophysiology of the disease is not completely known. Based on indocyanine green angiography (ICG), which revealed increased permeability of choroidal vessels, and optical coherence tomography (OCT) showing increased choroidal thickness, choroidal vasculopathy is assumed to be the primary cause of CSC...
2024: Ceská a Slovenská Oftalmologie
https://read.qxmd.com/read/38531003/widefield-swept-source-optical-coherence-tomography-angiography-metrics-as-predictors-of-anti-vegf-treatment-in-retinal-vein-occlusions
#25
JOURNAL ARTICLE
Matthew J Finn, Grace Baldwin, Ines Lains, Itika Garg, Hannah Wescott, Filippos Vingopoulos, Rebecca Zeng, Hanna Choi, Jack Tracy, Peyman Razavi, Diane Sayeh, Nimesh A Patel, David M Wu, Demetrios G Vavvas, John B Miller
BACKGROUND AND OBJECTIVE: Our objective was to assess baseline widefield swept-source optical coherence tomography angiography (WF SSOCTA) microvascular metrics as predictors for the number of anti-vascular endothelial growth factor (VEGF) injections and visual acuity (VA) at 12-months follow-up in patients with retinal vein occlusion (RVO). PATIENTS AND METHODS: This was a prospective study including 49 RVO eyes from 49 patients who had not received an anti-VEGF injection for at least 3 months prior to imaging...
March 1, 2024: Ophthalmic Surgery, Lasers & Imaging Retina
https://read.qxmd.com/read/38530568/efficacy-safety-and-immunogenicity-of-sun-s-ranibizumab-biosimilar-in-neovascular-age-related-macular-degeneration-a-phase-3-double-blind-comparative-study
#26
JOURNAL ARTICLE
Asim K Ghosh, Usha S Nikumbh, Chaitanya K Shukla, Rohit S Laul, Abhishek Dixit, Santosh K Mahapatra, Sameera Nayak, Urmil M Shah, Sandeep Parwal, Narendran Venkatapathy, Natasha Radhakrishnan, Anup Kelgaonkar, Sandeep Saxena, Divyansh Mishra, Vivek Pravin Dave, Perwez Khan, Manojkumar R Saswade, Malli S Shantilal, Kim Ramasamy, Smitha Sreekanta, Mandodari Rajurkar, Maulik Doshi, Sapan Behera, Piyush Patel, Shilpi Dhawan, Lalit Lakhwani
INTRODUCTION: The study aimed to evaluate comparability in terms of efficacy, safety and immunogenicity of Sun's ranibizumab biosimilar with reference ranibizumab in patients with neovascular age-related macular degeneration (nAMD). METHODS: This prospective, randomised, double-blind, two-group, parallel-arm, multicentre, phase 3 comparative study included patients with nAMD ≥ 50 years, randomised (in a 2:1 ratio) in a double-blind manner to receive 0...
March 26, 2024: Ophthalmology and Therapy
https://read.qxmd.com/read/38530567/enhancing-diabetic-macular-edema-treatment-outcomes-exploring-the-esaso-classification-and-structural-oct-biomarkers
#27
JOURNAL ARTICLE
Giacomo Panozzo, Maria V Cicinelli, Giulia Dalla Mura, Diana Giannarelli, Maria Vadalà, Vincenza Bonfiglio, Giovanni Bellisario, Francesco Bandello
INTRODUCTION: This study assessed the European School of Advanced Studies in Ophthalmology (ESASO) classification's prognostic value for diabetic macular edema (DME) in predicting intravitreal therapy outcomes. METHODS: In this retrospective, multicenter study, patients aged > 50 years with type 1 or 2 diabetes and DME received intravitreal antivascular endothelial growth factor (anti-VEGF) agents (ranibizumab, bevacizumab, and aflibercept) or steroids (dexamethasone)...
March 26, 2024: Ophthalmology and Therapy
https://read.qxmd.com/read/38529446/topical-dorzolamide-as-adjunctive-treatment-with-intravitreal-bevacizumab-in-bilateral-diabetic-macular-edema
#28
JOURNAL ARTICLE
Ata Sadr, Meisam Sargazi, Shahram Banaie, Mahdi Asani, Hassan Mehrad Majd, Seyed Omid Mohammadi, Alireza Maleki
BACKGROUND:  Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is accepted as the gold standard treatment for center-involving diabetic macular edema (CI-DME). Adjunctive administration of topical dorzolamide may enhance the therapeutic effects of anti-VEGF agents. In this study, we compared the efficacy of topical dorzolamide plus intravitreal injection of bevacizumab (IVB) versus IVB alone in patients with bilateral DME. METHODS: This prospective, randomized contralateral eye study was carried out in a tertiary referral ophthalmology center, Al-Zahra Eye Hospital, Zahedan, Iran, between April 2021 and April 2022...
February 2024: Curēus
https://read.qxmd.com/read/38524380/cell-specific-systemic-immune-signatures-associated-with-treatment-burden-in-neovascular-age-related-macular-degeneration
#29
JOURNAL ARTICLE
Joseph B Lin, Andrea Santeford, Darksha Usmani, Aaditya V Shah, Philip A Ruzycki, Rajendra S Apte
PURPOSE: Choroidal neovascularization (CNV) accounts for the majority of severe vision loss in neovascular age-related macular degeneration (AMD). Despite therapies that target VEGF, patients are often under-responsive, require frequent eye injections to control disease, and eventually lose some vision despite chronic therapy implicating a multifactorial etiology in treatment response. Genetic studies implicate systemic immunity in AMD and systemic immune cells accumulate within CNV lesions, yet a role for these cells in anti-VEGF response remains undetermined...
2024: Ophthalmol Sci
https://read.qxmd.com/read/38524332/treatment-outcomes-for-maculopathy-secondary-to-retinal-vein-occlusion-in-afghanistan
#30
JOURNAL ARTICLE
Mohammad Delsoz, Sayed Hamid Mousavi, Sher A Aslam
OBJECTIVES: The objective of this study was to investigate the efficacy of intravitreal antivascular endothelial growth factor (VEGF) therapy in the treatment of macular edema secondary to retinal vein occlusion (RVO) in Afghanistan. METHODS: A retrospective analysis was conducted of all RVO cases that underwent intravitreal ant-VEGF injection at the two leading hospitals in Kabul. The main outcome measures were visual acuity and central retinal thickness as determined by optical coherence tomography...
2024: Oman Journal of Ophthalmology
https://read.qxmd.com/read/38522978/correlation-between-serum-cytokine-levels-and-the-effect-of-allogeneic-serum-based-eye-drops
#31
JOURNAL ARTICLE
Katarzyna Chmielewska, Joanna Janus, Agata Mikołowska, Karolina Wrzodak, Marta Stącel, Jolanta Antoniewicz-Papis
INTRODUCTION: The Institute of Hematology and Transfusion Medicine (IHTM) in Warsaw has produced autologous serum eye drops (ASEDs) for the treatment of Dry Eye Syndrome (DES) since 1991. In 2019, IHTM introduced allogeneic tears (alloSEDs) for patients on long-term treatment. MATERIALS AND METHODS: 114 patients who applied alloSEDs were included in the study.They were asked to complete the OSDI questionnaire before and after using ASEDs and 100 units of alloSEDs drops from each donation...
March 14, 2024: Transfusion and Apheresis Science
https://read.qxmd.com/read/38522916/molecular-basis-of-angiogenesis-and-its-application
#32
JOURNAL ARTICLE
Napoleone Ferrara
Angiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelial growth factor (VEGF, VEGF-A) as an endothelial cell-specific mitogen and angiogenic factor...
2024: Keio Journal of Medicine
https://read.qxmd.com/read/38521951/the-role-of-long-noncoding-rnas-in-ocular-angiogenesis-and-vascular-oculopathy
#33
REVIEW
Pranali Gandhi, Yuzhi Wang, Guigang Li, Shusheng Wang
Long noncoding RNAs (lncRNAs) are RNA transcripts over 200 nucleotides in length that do not code for proteins. Initially considered a genomic mystery, an increasing number of lncRNAs have been shown to have vital roles in physiological and pathological conditions by regulating gene expression through diverse mechanisms depending on their subcellular localization. Dysregulated angiogenesis is responsible for various vascular oculopathies, including diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, and corneal neovascularization...
March 23, 2024: Cell & Bioscience
https://read.qxmd.com/read/38516283/quantifying-fluid-and-function-in-suboptimal-responders-switched-from-an-anti-vascular-endothelial-growth-factor-vegf-to-faricimab
#34
JOURNAL ARTICLE
David Sutter, Abigail Anderson, Sheila Wheatley, Veeral Sheth
Background Anti-vascular endothelial growth factor (VEGF) injections have been successful in reducing vision loss from neovascular age-related macular degeneration, a leading cause of blindness. Due to the high treatment burden and suboptimal responses, switching to bi-specific faricimab treatment may lead to improved outcomes. Methods This retrospective chart review evaluated if suboptimal responders to anti-VEGF injections had better outcomes when switched to faricimab. Suboptimal responders were defined as patients with a history of >3 months of injections and the presence of fluid after ≥3 injections...
March 2024: Curēus
https://read.qxmd.com/read/38507189/analytical-and-functional-similarity-of-aflibercept-biosimilar-abp%C3%A2-938-with-aflibercept-reference-product
#35
JOURNAL ARTICLE
Neungseon Seo, Xiaoyan Guan, Tian Wang, Hyo S Helen Chung, Mats Wikström, Rupa Padaki, Kevin Kalenian, Scott Kuhns, Kelli Matthies, Jill Crouse-Zeineddini, Helen Y Wong, Michael Ng, Ian N Foltz, Shawn Cao, Jennifer Liu
INTRODUCTION: ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders. This study was designed to provide a comparative analytical assessment of the structural and functional attributes of ABP 938 and aflibercept RP sourced from the United States (US) and the European Union (EU). METHODS: Structural and functional characterization studies were performed using state-of-the-art analytical techniques that were appropriate to assess relevant quality attributes and capable of detecting qualitative and quantitative differences in primary structure, higher-order structure and biophysical properties, product-related substances and impurities, general properties, and biological activities...
March 20, 2024: Ophthalmology and Therapy
https://read.qxmd.com/read/38504533/emodin-suppresses-alkali-burn-induced-corneal-inflammation-and-neovascularization-by-the-vascular-endothelial-growth-factor-receptor-2-signaling-pathway
#36
JOURNAL ARTICLE
Zheng Xueying, Guo Liang, Lai Siyi, L I Fengyue, Liang Mingli, Liu Wanting, Meng Chun, Liu Guanghui
OBJECTIVE: To investigate the effects of emodin on alkali burn-induced corneal inflammation and neovascularization. METHODS: The ability of emodin to target vascular endothelial growth factor receptor 2 (VEGFR2) was predicted by molecular docking. The effects of emodin on the invasion, migration, and proliferation of human umbilical vein endothelial cells (HUVEC) were determined by cell counting kit-8, Transwell, and tube formation assays. Analysis of apoptosis was performed by flow cytometry...
April 2024: Journal of Traditional Chinese Medicine
https://read.qxmd.com/read/38498296/the-role-of-endothelial-growth-factor-and-tear-levels-in-diabetic-retinopathy-in-type-2-diabetes
#37
JOURNAL ARTICLE
Hassan Hashemi, Hanieh Ahmadi, Zahra Rostami, Abbas Alishahi, Zahra Heidari
PURPOSE: To evaluate the tear level of VEGF and the quantity of tear film in type 2 diabetic patients. METHODS: Thirty patients with diabetic retinopathy (DR group) and 30 patients with no DR (NDR group), and 30 healthy subjects with age and gender matching were enrolled in this prospective comparative study. The tear samples were collected using the Schirmer strips, and the amount of moisture absorbed by the strips was used to determine the quantitative level of the tear film...
March 18, 2024: International Ophthalmology
https://read.qxmd.com/read/38494487/preserving-visual-acuity-a-compelling-12-year-case-study-of-controlling-neovascular-age-related-macular-degeneration
#38
JOURNAL ARTICLE
Rita O Tomás, António Campos, Nuno Oliveira, Pedro Soares, João P Sousa
INTRODUCTION: In neovascular age-related macular degeneration (nAMD) trials, anti-VEGF injection frequency decreases after the first year, while outcomes remain primarily related to the number of injections. To the best of our knowledge, there are no reports of maintaining the best corrected visual acuity (BCVA) for more than 7 years in extension studies. OBJECTIVE: To report a 12-year follow-up of a real-world case of nAMD where BCVA was preserved from declining...
March 18, 2024: BMC Ophthalmology
https://read.qxmd.com/read/38491380/artificial-intelligence-in-age-related-macular-degeneration-state-of-the-art-and-recent-updates
#39
REVIEW
Emanuele Crincoli, Riccardo Sacconi, Lea Querques, Giuseppe Querques
Age related macular degeneration (AMD) represents a leading cause of vision loss and it is expected to affect 288 million people by 2040. During the last decade, machine learning technologies have shown great potential to revolutionize clinical management of AMD and support research for a better understanding of the disease. The aim of this review is to provide a panoramic description of all the applications of AI to AMD management and screening that have been analyzed in recent past literature. Deep learning (DL) can be effectively used to diagnose AMD, to predict short term risk of exudation and need for injections within the next 2 years...
March 15, 2024: BMC Ophthalmology
https://read.qxmd.com/read/38490478/tear-cytokine-levels-are-reduced-in-patients-treated-with-intravitreal-injections
#40
JOURNAL ARTICLE
Agni Malmin, Vilde M Thomseth, Per T Førland, HansC D Aass, Sjur Reppe, Markus V Olsen, Birger Lindtjørn, Xiangjun Chen, IngaB K Haugen, Tor P Utheim, Vegard A Forsaa
PURPOSE: To investigate cytokine levels in the tear fluid of patients receiving serial intravitreal injections (IVI) with anti-vascular endothelial growth factor (anti-VEGF) for neovascular age-related macular degeneration (nAMD). METHODS: Concentrations of six cytokines (IFN-γ, IL-1β, IL-6, IL-8, TNF and VEGF) in tears of patients receiving anti-VEGF in one eye were assayed using multiplex cytometric bead array. The fellow untreated eye served as control...
March 13, 2024: Ocular Surface
keyword
keyword
4979
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.